There have been concerns recently reported in the news about the supposed adverse effects of a certain type of medication used to treat blood pressure and renal problems. Concerns were raised about a possible risk of infection from SARS-Cov-2 (the new coronavirus) and an increase in the severity of the clinical symptoms.
What is the medication?
This relates to a specific type of medication called Angiotensin-Converting Enzyme inhibitors (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs).
ACE inhibitors include ramipril, lisinopril, enalapril. ARBs include losartan, candersartan and valsartan.
What is the current advice?
The Council on Hypertension of the European Society of Cardiology wishes to highlight the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak. The organization strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy as there is no clinical or scientific evidence to suggest that treatment with ACEi or ARBs should be discontinued because of the Covid-19 infection. [1]
This recommendation is similarly supported by other professional societies, such as the International Society of Hypertension [2] and the Renal Association UK, who have released supporting statements advising people taking these medications to continue to take them.[3]
What does this mean for me?
The situation is always changing with new research and evidence coming to light. Advice may change in the future. However current advice from 17th March 2020 is for patients to continue with their usual ACE inhibitors or ARBs. Stopping the medication can lead to the worsening of pre-existing conditions and is not recommended. If you have any concerns, please discuss with your personal doctor.
References
[1]Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers.13 Mar 2020. Prof. Giovanni de Simone, Chair, ESC Council on Hypertension, On behalf of the Nucleus Members
[2] A statement from the International Society of Hypertension on COVID-19, 16th March 2020
[3] The Renal Association, UK position statement for patients: novel corona virus infection and the use of blood pressure medications, 15th March 2020
[4] Sparks MA, Hiremath S et al. “The Coronavirus Conundrum: ACE2 and Hypertension Edition” NephJC http://www.nephjc.com/news/covidace2 accessed March 17, 2020
Δρ Αίμιλη Ηρακλέους
Προσωπικος Ιατρος ΓΕΣΥ
Ιατρικό Κέντρο “Ο Απόστολος Λουκάς”
Διαβάστε το βιογραφικό της Δρ Αίμιλης Ηρακλέους.